September 3rd, 2022 - MediLink Therapetutics announced that YL202 has been cleared for its IND application by the U.S. Food and Drug Administration for Phase I first-in-human study. YL202 is MediLink's second compound based on its proprietary "Tumor Microenviroment Activable LINker (TMALIN)" technology platform. The Phase I dose escalation study of the first product YL201 is ongoing, and the IND clearance for YL202 will provide further clinical proof for TMALIN technology.
About MediLink Therapeutics
Founded in 2020, MediLink Therapeutics focuses on developing innovative conjugated drugs for unmet medical needs, and has built a differentiated proprietary "Tumor Microenviroment Activable LINker (TMALIN) ADC technology platform.
1st patient dosed with product YL201 in the United States
Jiangsu Public TV visit MediLink